Friday, 14 August 2026European Markets
Facts you can rely on·101 entities·4,806 sourced facts
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 17, 2026

Top Stock Reports for GE Aerospace, Shell & McKesson

View original at finance.yahoo.com
Top Stock Reports for GE Aerospace, Shell & McKesson Tuesday, March 17, 2026 The Zacks Research Daily presents the best research output of our analyst team…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Elite Pharmaceuticals remains sensitive to generic pricing pressure, DEA quota and API supply constraints, and customer concentration

    60% confidence
  • Geospace's valuation implies investors are pricing risk, leaving upside if contract delivery improves visibility

    60% confidence
  • McKesson faces risks from revenue concentration with large customers, regulatory headwinds such as IRA and DSCSA, and execution challenges from the Medical-Surgical separation and ongoing M&A integration

    60% confidence
  • Shell achieved structural cost reductions ahead of schedule and portfolio simplification that have improved efficiency and balance-sheet flexibility

    60% confidence
  • Rising U.S. & international defense budgets, geopolitical tensions, positive airline & airframer dynamics and robust demand for commercial air travel augur well for GE Aerospace

    60% confidence
  • Shell's net debt increased, while Chemicals and Renewables continue to weigh on returns amid weak margins

    60% confidence
  • For Shell, strengths are offset by cyclical and segment-specific risks, justifying a neutral stance

    60% confidence
  • Shell's LNG franchise remains a long-term strength, with solid sales growth and clear demand visibility

    60% confidence
  • McKesson's strategic acquisitions such as PRISM and Core Ventures enhance its oncology footprint

    60% confidence
  • Rising labor and transportation costs, combined with variability in 3PL revenues, add further margin uncertainty for McKesson

    60% confidence
  • Elite Pharmaceuticals' stable base from amphetamine IR and ER generics supports cash flow, while new launches and a growing pipeline enhance revenue visibility

    60% confidence
  • GE Aerospace has been dealing with high costs and expenses related to certain projects and restructuring activities, which are likely to affect its margins and profitability

    60% confidence
  • Shell demonstrated resilient cash generation in 2025, delivering robust operating and free cash flows, supporting shareholder returns

    60% confidence
  • Geospace's near-term results reflect cyclical energy demand and margin pressure from low rental utilization

    60% confidence
  • Geospace Technologies offers exposure to long-cycle infrastructure and energy markets across Smart Water, Intelligent Industrial and Energy Solutions

    60% confidence
  • Geospace Technologies' Intelligent Industrial is developing subscription-based security products, such as the Heartbeat Detector, that add predictable revenue

    60% confidence
  • Elite Pharmaceuticals' investment thesis centers on its expanding presence in ADHD therapeutics, led by its generic lisdexamfetamine franchise, driving strong volume growth

    60% confidence
  • Shell demonstrated resilient cash generation in 2025, delivering robust operating and free cash flows, supporting shareholder returns

    60% confidence
  • McKesson's strong cash flow generation and disciplined capital allocation underpin long-term adjusted EPS growth of 12-14%

    60% confidence
  • Shell's earnings and revenue declined year over year, highlighting exposure to commodity price cycles

    60% confidence
  • GE Aerospace's portfolio-reshaping actions are likely to unlock value for its shareholders

    60% confidence
  • McKesson is delivering record revenues and expanding margins, supported by growth in specialty pharmaceuticals, oncology services, RxTS, and GLP-1 distribution

    60% confidence
  • GE Aerospace has been dealing with high costs and expenses related to certain projects and restructuring activities, which are likely to affect its margins and profitability

    60% confidence
  • Geospace's Intelligent Industrial is developing subscription-based security products, such as the Heartbeat Detector, that add predictable revenue

    60% confidence
  • Shell's net debt increased, while Chemicals and Renewables continue to weigh on returns amid weak margins

    60% confidence
  • Geospace Technologies' Smart Water benefits from demand for water infrastructure modernization and Hydroconn adoption, while the Aquana platform supports a shift to recurring revenue

    60% confidence
  • Geospace's liquidity has declined as working capital builds for contracts and receivable concentration adds risk

    60% confidence
  • GE Aerospace expects organic revenues to grow in the low-double-digit range from the year-ago level for 2026

    60% confidence
  • Geospace Technologies' $90 million PRM contract provides revenue visibility, and Pioneer land nodes expand GEOS' role in seismic exploration

    60% confidence
  • For 2026, GE Aerospace expects organic revenues to grow in the low-double-digit range from the year-ago level

    60% confidence